Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 19Thoracic 2Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Dermatologic 2Breast 2NET 1Lymphoid 1Gynecologic 1Endocrine 1Classical hematology 1

Conditions

Ovarian Neoplasms 1006Uterine Cervical Neoplasms 420Endometrial Neoplasms 350Carcinoma, Non-Small-Cell Lung 292Breast Neoplasms 292Neoplasms 238Colorectal Neoplasms 233Fallopian Tube Neoplasms 211Stomach Neoplasms 192Pancreatic Neoplasms 184Melanoma 157Prostatic Neoplasms 152Triple Negative Breast Neoplasms 148Carcinoma, Ovarian Epithelial 147Lung Neoplasms 136Neoplasm Metastasis 133Squamous Cell Carcinoma of Head and Neck 131Carcinoma, Renal Cell 130Head and Neck Neoplasms 122Esophageal Neoplasms 121Urinary Bladder Neoplasms 112Small Cell Lung Carcinoma 90Sarcoma 80Carcinoma, Hepatocellular 76Recurrence 70Carcinoma, Transitional Cell 70Uterine Cervical Dysplasia 66Papillomavirus Infections 66Colonic Neoplasms 59Cholangiocarcinoma 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Diseases × Gynecologic × Clear all
NCT02837991 2020-06-04

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Celldex Therapeutics

Phase 1 Terminated
16 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡